Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387642034> ?p ?o ?g. }
- W4387642034 abstract "Dupilumab, omalizumab, and mepolizumab are the three biologics currently approved for use in CRSwNP in Canada. Despite evidence of efficacy, their cost-effectiveness, which is a key factor influencing prescribing patterns, has not yet been compared to each other.A cost-effectiveness model using quality-adjusted life years (QALYs) was constructed using a Decision Tree Markov analysis. A third-party healthcare payer perspective and a 10-year time horizon was used. A willingness-to-pay (WTP) threshold of 50,000 Canadian dollars (CAD) per QALY was used to determine cost-effectiveness. Dupilumab, omalizumab, and mepolizumab were each compared to each other.Omalizumab was the most cost-effective biologic using current estimates of cost and efficacy in CRSwNP. Using omalizumab as a baseline, dupilumab had an ICER of $235,305/QALY. Mepolizumab was dominated by omalizumab and dupilumab at the current drug prices and estimates of efficacy. Sensitivity analyses determined that when increasing the WTP threshold to $150,000/QALY, dupilumab became cost-effective compared to omalizumab in 22.5% of simulation scenarios. Additionally, altering dosing frequency had a significant effect on cost-effectiveness.When comparing the relative cost-effectiveness of biologics in recalcitrant CRSwNP, omalizumab currently appears to be the most cost-effective option. Future reductions in drug prices, adjustments to currently approved dosing regimens, better patient selection, and improvements in sinus surgery outcomes will challenge the current cost-effectiveness models and necessitate reassessment as treatments for CRSwNP continue to evolve." @default.
- W4387642034 created "2023-10-15" @default.
- W4387642034 creator A5014532937 @default.
- W4387642034 creator A5031013320 @default.
- W4387642034 creator A5037758035 @default.
- W4387642034 creator A5073837987 @default.
- W4387642034 creator A5083299658 @default.
- W4387642034 date "2023-10-14" @default.
- W4387642034 modified "2023-10-18" @default.
- W4387642034 title "Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada" @default.
- W4387642034 cites W1537778055 @default.
- W4387642034 cites W1757717878 @default.
- W4387642034 cites W2006906070 @default.
- W4387642034 cites W2028306635 @default.
- W4387642034 cites W2033156884 @default.
- W4387642034 cites W2067316800 @default.
- W4387642034 cites W2077684968 @default.
- W4387642034 cites W2085363308 @default.
- W4387642034 cites W2091048892 @default.
- W4387642034 cites W2128911553 @default.
- W4387642034 cites W2129494861 @default.
- W4387642034 cites W2137689065 @default.
- W4387642034 cites W2166931169 @default.
- W4387642034 cites W2313535889 @default.
- W4387642034 cites W2461032133 @default.
- W4387642034 cites W2471128678 @default.
- W4387642034 cites W2554368353 @default.
- W4387642034 cites W2587035298 @default.
- W4387642034 cites W2594220482 @default.
- W4387642034 cites W2752341816 @default.
- W4387642034 cites W2758494457 @default.
- W4387642034 cites W2799887732 @default.
- W4387642034 cites W2803602511 @default.
- W4387642034 cites W2901619788 @default.
- W4387642034 cites W2912558194 @default.
- W4387642034 cites W2943295610 @default.
- W4387642034 cites W2946585587 @default.
- W4387642034 cites W2946967483 @default.
- W4387642034 cites W2967090416 @default.
- W4387642034 cites W2973437633 @default.
- W4387642034 cites W2989575450 @default.
- W4387642034 cites W3014934509 @default.
- W4387642034 cites W3034146395 @default.
- W4387642034 cites W3038134106 @default.
- W4387642034 cites W3080596765 @default.
- W4387642034 cites W3092367507 @default.
- W4387642034 cites W3139127912 @default.
- W4387642034 cites W3152988358 @default.
- W4387642034 cites W3186381365 @default.
- W4387642034 cites W3200207529 @default.
- W4387642034 cites W4220967255 @default.
- W4387642034 doi "https://doi.org/10.1186/s13223-023-00823-1" @default.
- W4387642034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37838713" @default.
- W4387642034 hasPublicationYear "2023" @default.
- W4387642034 type Work @default.
- W4387642034 citedByCount "0" @default.
- W4387642034 crossrefType "journal-article" @default.
- W4387642034 hasAuthorship W4387642034A5014532937 @default.
- W4387642034 hasAuthorship W4387642034A5031013320 @default.
- W4387642034 hasAuthorship W4387642034A5037758035 @default.
- W4387642034 hasAuthorship W4387642034A5073837987 @default.
- W4387642034 hasAuthorship W4387642034A5083299658 @default.
- W4387642034 hasBestOaLocation W43876420341 @default.
- W4387642034 hasConcept C112930515 @default.
- W4387642034 hasConcept C126322002 @default.
- W4387642034 hasConcept C141105273 @default.
- W4387642034 hasConcept C159654299 @default.
- W4387642034 hasConcept C162324750 @default.
- W4387642034 hasConcept C175444787 @default.
- W4387642034 hasConcept C177713679 @default.
- W4387642034 hasConcept C203014093 @default.
- W4387642034 hasConcept C2776042228 @default.
- W4387642034 hasConcept C2777037409 @default.
- W4387642034 hasConcept C2777288759 @default.
- W4387642034 hasConcept C2777364431 @default.
- W4387642034 hasConcept C2777832160 @default.
- W4387642034 hasConcept C2778564945 @default.
- W4387642034 hasConcept C2779824493 @default.
- W4387642034 hasConcept C3019080777 @default.
- W4387642034 hasConcept C64332521 @default.
- W4387642034 hasConcept C71924100 @default.
- W4387642034 hasConceptScore W4387642034C112930515 @default.
- W4387642034 hasConceptScore W4387642034C126322002 @default.
- W4387642034 hasConceptScore W4387642034C141105273 @default.
- W4387642034 hasConceptScore W4387642034C159654299 @default.
- W4387642034 hasConceptScore W4387642034C162324750 @default.
- W4387642034 hasConceptScore W4387642034C175444787 @default.
- W4387642034 hasConceptScore W4387642034C177713679 @default.
- W4387642034 hasConceptScore W4387642034C203014093 @default.
- W4387642034 hasConceptScore W4387642034C2776042228 @default.
- W4387642034 hasConceptScore W4387642034C2777037409 @default.
- W4387642034 hasConceptScore W4387642034C2777288759 @default.
- W4387642034 hasConceptScore W4387642034C2777364431 @default.
- W4387642034 hasConceptScore W4387642034C2777832160 @default.
- W4387642034 hasConceptScore W4387642034C2778564945 @default.
- W4387642034 hasConceptScore W4387642034C2779824493 @default.
- W4387642034 hasConceptScore W4387642034C3019080777 @default.
- W4387642034 hasConceptScore W4387642034C64332521 @default.
- W4387642034 hasConceptScore W4387642034C71924100 @default.
- W4387642034 hasIssue "1" @default.